In vivo effects of afobazole (2-mercaptobenzimidazole derivative) on the 7,12-dimethylbenz[α]anthracene-inducedoncogene and suppressor gene expression

In Vivo

Volumn 21, Issue 6, 2007, Pages 1059-1064

  Szanyi, István ^a   Lujber, László ^a   Gerlinger, Imre ^a   Pytel, József ^a   Bauer, Miklós ^a   Csejtey, András ^b   Szele, Eszter ^a   Gombos, Katalin ^a   Kiss, István ^a   Seredenin, Sergey ^c   Yarkova, Milada ^c   Ember, István ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

^b Markusovszky Teaching Hospital   (Hungary)

^c INSTITUTE OF PHARMACOLOGY   (Russian Federation)

Author keywords

2 mercaptobenzimidazole; Afobazole; Chemopreventive effect; Oncogene; Suppressor gene expression

Indexed keywords

AFOBAZOLE; ANTINEOPLASTIC AGENT; DIMETHYLBENZ[A]ANTHRACENE; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CBA MOUSE; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; IN VIVO STUDY; MOUSE; NEOPLASM; NONHUMAN; ONCOGENE; ONCOGENE H RAS; ORGAN DISTRIBUTION; PROTEIN EXPRESSION; SUPPRESSOR GENE;

EID: 37349109295     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Kosmidis PA: Head and neck cancer. Euro Cancer News 6: 9-13, 1993.
2. Csuka O, Olasz J, Juhasz A, Hargitai A, Remenar E and Kasler M: Genetic marker analysis in head and neck cancer. Hungarian Oncol 45: 161-167, 2001.
3. Ember I, Kiss I, Gombköto G, Müller E and Szeremi M: Oncogene and suppressor gene expression as a biomarker for ethylene oxide exposure. Cancer Detect Prev 22: 241-245, 1998.
4. Perjesi P, Bayer Z and Ember I: Effect of E-2-(4′-methoxy-benzylidene)-1-benzosuberone on the 7,12-dimethyl-benz(α) anthracene-induced onco/suppressor gene action in vivo I,: a 24-hour experiment. Anticancer Res 20: 475-482, 2000.
5. Perjesi P, Gyöngyi Z and Bayer Z: Effect of E-2-(4′-methoxybenzylidene)-1-benzosuberone on the 7,12-dimethyl-benz(α)anthracene-induced onco/suppressor gene action in vivo II,: a 48-hour experiment. Anticancer Res 20: 1839-1848, 2000.
6. Perjesi P, Ember I, Bozak RE, Nadasi E, Rozmer Z, Varjas T and Hicks RJ: Effect of the chalcone analog E,E-bis(2-hydroxybenzilidene)acetone on the 7,12 dimethylbenz(α) anthracene-induced Ha-ras gene activity in vivo. In Vivo 20: 141-146, 2006.
7. Plotnikov MB, Saratikov AS, Plotnikova TM, Khazanov VA and Panina OP: Antihypoxic and antioxidative properties of bemitil. Bull Eksp Biol Med 5: 583-585, 1989.
8. Varjas T, Nadasi E, Pusztai Z, Ember I, Gyöngyi Z, Durnjev X Kiss I: Anticarcinogenic effect of bemitilin a gene expression model. International Conference on Apoptosis, Athens, Greece, May 25-28 2001. Anticancer Res 21: 1620-21, 2001.
9. Zahanatev AK, Durnev AD and Seredenin SB: The antimutagenic activity of afobazole studied in vivo. Eksp Klin Farmakol 2: 57-59, 2000.
10. Osaka M, Matsuo S, Koh T and Sugiyama T: Loss of heterozygosity at the N-ras locus in 7,12-dimethylbenz(α) anthracene-induced rat leukemia. Mol Carcinog 18: 206-212, 1997.
11. Walker DR, Bond JP, Tarone RE, Harris CC, Makalowski W, Boguski MS and Greenblatt MS: Evolutionary conservation and somatic mutation hotspot maps of p53: correlation with p53 protein structural and functional features. Oncogene 18: 211-218, 1999.
12. Leonard JH, Kearsley JH, Chenevix-Trench G and Hayward NK: Analysis of gene amplification in head-and-neck squamous cell carcinoma. Int J Cancer 48: 511-515, 1991.
13. Kozma L, Kiss I, Nagy A, Szakall SZ and Ember I: Investigation of c-myc and K-ras amplification in renal clear cell adenocarcinoma. Cancer Lett 111: 127-131, 1997.
14. Ember I, Kiss I, Ghodratollah N and Raposa T: Effect of ABVD therapeutic protocol on oncogene and tumor suppressor gene expression in CBA/CA mice. Anticancer Res 18: 1149-1152, 1998.
15. Friedrich RE, Giese M, Riethdorf S and Loning T: P53 mutation in smears of oral squamous carcinoma. Anticancer Res 20: 4927-4930, 2000.
16. Yanamoto S, Kawasaki G, Yoshitomi I and Mizuno A: P53, mdm2 and p21 expression in oral sqamous cell carcinomas: relationship with clinicopathologic factors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 94: 593-600, 2002.
17. Ember I, Kiss I and Vermes E: Early effect of cyclophosphamide on oncogene expression in vivo. In Vivo 12: 201-208, 1998.
18. Ember I, Kiss I and Pusztai Z: Effect of 7,12-dimethylbenz(α) anthracene on onco/suppressor gene action in vivo. A short-term experiment. Anticancer Res 18: 445-448, 1998.
19. Pelling JC, Ernst SM, Strawhecker JM, Johnson JA, Nairn RS and Slaga TJ: Elevated expression of Ha-ras is an early event in two-stage carcinogenesis in SENCAR mice. Carcinogenesis 9: 1599-1602, 1986.
20. Pelling JC, Fisher SM, Neades R, Strawecker J and Schweicker L: Elevated expression and point mutation of the Ha-ras protooncogene in mouse skin turnors promoted by benzyl peroxide and other promoting agents. Carcinogenesis 8: 1481-1484, 1987.
21. Wilson NM, Christou M, Tumer CR, Wrighton SA and Jefcoate CR: Binding and metabolism of benzo(α)pyrene and 7,12-dimethylbenz(α)anthracene by seven purified forms of cytoehrome P-450. Carcinogenesis 5: 1475-1483, 1984.
22. Silkina IV, Zenina TA, Seredenin SB and Mirzoian RS: Effect of afobazole on the accumulation of free radical oxidation products and the catalase activity in rats with cerebral ischemia. Eksp Klin Farmakol 4: 47-50, 2006.
23. Zhanataev AK, Durnev AD and Seredin SB: Antimutagenic activity of afobazole in various regiments of treatment. Bull Exp Biol Med 11: 1077-1079, 2000.